Fig. S7.

Marimastat blocks forward neuroblast migration. (A–C) Focal administration of the dual MMP-2/MMP-9 inhibitor Marimastat (1 µ M/0.1 µL) (Tocris) increased the diameter of the proximal RMS (B₂) but decreased the diameter of the distal RMS (B₁), compared with control (DMSO) application (A₂ and A₁, respectively) with secretagogin⁺ cells accumulating upstream the application site. The effect of Marimmastat is quantified in C. (Scale bars: 100 µm in A and B; 20 µm in A₁, A₂, B₁, and B₂.) *P < 0.05.